This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Jiangsu University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Wenrong Xu
Introduction
Wenrong Xu is a notable inventor based in Zhenjiang, China. He has made significant strides in the field of drug delivery systems through his innovative research and development. His work focuses on engineered nanovesicle drug loading systems, which have the potential to revolutionize cancer treatment.
Latest Patents
Wenrong Xu holds a patent for a groundbreaking invention titled "Superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery, and preparation method thereof." This patent describes a biological preparation that utilizes superparamagnetism-modified and neutrophil exosome biomimetic vesicles for targeted drug delivery. The preparation specifically acts on tumor cell lines, inducing apoptosis and inhibiting tumor growth. It has been shown to significantly extend the survival time of mice and improve the efficacy of drugs against cancers. Wenrong Xu has 1 patent to his name.
Career Highlights
Wenrong Xu is affiliated with Jiangsu University, where he contributes to advancing research in biomedical engineering. His work has garnered attention for its innovative approach to addressing challenges in drug delivery systems.
Collaborations
Wenrong Xu collaborates with esteemed colleagues, including Cheng Ji and Jiahui Zhang, who share his commitment to advancing scientific knowledge and practical applications in their field.
Conclusion
Wenrong Xu's contributions to the field of drug delivery through his innovative patent highlight his role as a leading inventor in biomedical engineering. His work not only enhances the understanding of targeted therapies but also paves the way for future advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile